Other non-TNF-α treatments,Such as Abatacept, a novel biologic already approved for the treatment of patients with RA, interferes with T cell activation and prompts the polarization of adipose tissue macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotype, thereby reducing adipose tissue inflammation to improve insulin sensitivity (118). The gene discussed is TNF; the disease is rheumatoid arthritis.